CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 133 enrolled
Drug / intervention
Insulin Lispro 6 Day (6D) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01134107
NCT01134107Phase 3Completed
CompareCT.gov

A Double-Blind, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients With Type 1 Diabetes Mellitus

Eli Lilly and Company·interventional·Posted May 31, 2010·Updated Apr 11, 2013

In Brief

A Phase 3 clinical trial evaluating Insulin Lispro 6 Day (6D) and Insulin Aspart 6 Day (6D) for Diabetes Mellitus, Type 1. Completed, enrolled 133 participants across 15 sites in 3 countries.

Detailed Summary

Patients will continue to use their current insulin pump for this study. Patients will receive insulin lispro and insulin aspart during this study. One medication will be taken for 12 weeks and then the other medication for 12 weeks. Neither the patient nor the study doctor will know which medication is being taken at any time. The order in which the two medications are taken will be determined by chance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesFrance, Germany, Hungary
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 31, 2010
Enrollment StartNov 1, 2010
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.1 years ago

Interventions

Insulin Lispro 6 Day (6D)drug

Administered by infusion pump for 12 week treatment period

Insulin Aspart 6 Day (6D)drug

Administered by infusion pump for 12 week treatment period